Navigation Links
Large-scale genomic analysis of prostate cancer unveiled
Date:6/25/2010

NEW YORK, June 24, 2010A unique collaboration among physician-scientists at Memorial Sloan-Kettering Cancer Center (MSKCC) has yielded the most comprehensive genomic analysis of prostate cancer to date. "Genomic studies in other cancer types have resulted in new drug targets and strategies to classify patients into clinically meaningful subgroups that improve treatment decisions," said senior study author Charles Sawyers, Chair of the Human Oncology and Pathogenesis Program at MSKCC and a HHMI investigator. "This first -ever database of its type brings us one step closer to achieving that goal in prostate cancer."

The study, published early online on June 24 in the journal Cancer Cell, provides a previously unavailable genomic analysis whose scope and size offers new insight leading to more effective diagnostic tests as well as future treatment options for prostate cancer patients.

"We have used all of our expertise and resources to complete a large-scale study of the changes in the genomes of patients' prostate cancers," says Dr. Sawyers, who explains that prostate tumor cells are very difficult to work with despite the fact that prostate cancer is the most common cancer in men. Consequently, there have been fewer genomic studies in prostate cancer compared to other tumor types such as lung cancer. "The ability to collect and analyze these tumor samples is a testament to the collaboration and expertise across many disciplines."

The MSKCC team, composed of members of the Human Oncology and Pathogenesis Program, urology, medicine and genitourinary oncology services, pathology, computational biology, and statistics departments, used an integrated, comprehensive approach to analyze 218 primary and metastatic samples and 12 cell lines. All samples were procured from patients treated by radical prostatectomy at MSKCC. The analysis revealed a much higher frequency of alterations in the androgen receptor pathway than previously suspected. Also, the pattern of DNA copy number alterations identified defined subsets of low-and high-risk disease beyond what is revealed by Gleason score.

"One of the holy grails of prostate cancer is to identify which tumors need to be aggressively treated and which don't," said Dr. Sawyers. "Ultimately, what we have learned could lead to the creation of a genetic-based test to determine which prostate cancers might become more virulent and require aggressive treatment and which tumors may not." According to Dr. Sawyers, "This data clarifies the role of several known cancer pathways and provides important clues into others. We have gained insight into the importance of androgen receptor statusand why some men respond to hormone therapy and others don't."


'/>"/>

Contact: Jeanne D'Agostino
dagostij@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Related medicine news :

1. Confronting infectious disease threats at large-scale international events
2. Genentech uses Complete Genomics human genome sequencing service to compare tumor and normal genome in patient with non-small cell lung cancer; results published in Nature
3. Breast Cancer Patients Often Confused by Genomic Testing
4. Improvements needed in genomic test result discussions
5. Lawrence Berkeley National Laboratory and OpenHelixTM Announce an Updated Free Tutorial Suite for VISTA: Tools for Comparative Genomics
6. SeqWright Advances Genomic Discovery With Isilon IQ
7. Researchers chart genomic map spanning over 2 dozen cancers
8. UCLA cancer researchers perform complete genomic sequencing of brain cancer cell line
9. Genomic surveillance of pandemic H1N1
10. The Institut Curie and Ipsogen Sign a Scientific Collaboration Agreement Relating to the Genomic Grade, a Molecular Diagnostic Tool for Breast Cancer
11. NeoGenomics Announces Executive Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , ... January 18, 2017 , ... ... asset protection and financial planning services to families and business owners in the ... aimed at supporting children with developmental disabilities. , The Lakemary Center is a ...
(Date:1/18/2017)... ... January 18, 2017 , ... Catalent ... for drugs, biologics and consumer health products, today announced that Mr. Michael Merges, ... upcoming WCBP Conference, to be held at the Mayflower Hotel, Washington DC, on ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... the revolutionary Active Brake Technology (ABT), an innovative braking system that allows skaters ... Brake Technology addresses one of the biggest concerns of beginner and intermediate skaters ...
(Date:1/17/2017)... Michigan (PRWEB) , ... January 17, 2017 , ... January is National Stalking Awareness ... who choose to lurk in the corners and commit the crime of stalking, a very ... use and addiction, an often overlooked factor in stalking and other crimes. , “Stalking: know ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... point of difference. Eden Activewear is a stand-out company for several differences from ... online and only manufacture on demand, this is called 'Agile' manufacturing - ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... , Jan. 18, 2017  Dermata Therapeutics, LLC, ... to treat a variety of dermatological diseases, announces ... DMT210, in a Phase 2 acne rosacea study. ... downregulate the proinflammatory cytokines in the skin responsible ... rosacea. This clinical trial, DMT210-003, ...
(Date:1/18/2017)... Safe Rx LLC and Good Day Pharmacy, ... Loveland, Colorado , today announced the availability ... Day locations.     "Patients with prescriptions prone ... storage," said Milton Cohen , President & CEO ... a cup of coffee, you can protect your children ...
(Date:1/18/2017)... In China , we say Health is ... China,s Healthy Strategy originates. 2016 is ... and Social Development of the People,s Republic of ... council of the People,s Republic of China ... plan, identifying medical devices as one of the main breakthrough ...
Breaking Medicine Technology: